Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

4 weeks ago 20

Jonathan Ponciano, The Motley Fool

Mon, February 23, 2026 astatine 9:21 AM CST 4 min read

Commodore Capital reported a merchantability of 850,000 shares of Nuvalent (NASDAQ:NUVL) successful its latest SEC filing dated February 17, 2026, with the estimated transaction worth astatine $83.81 cardinal based connected quarterly mean pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Commodore Capital sold 850,000 shares of Nuvalent during the 4th fourth of 2025. The estimated worth of these income was $83.81 cardinal based connected the mean closing terms for the period. The stake’s quarter-end worth declined by $65.75 million, a fig that includes the interaction of some trading and terms changes.

This was a nett sale, reducing Nuvalent’s stock of 13F AUM from 9.26% earlier the 4th to 3.68% after.
Top 5 holdings aft the filing:
- NASDAQ:RLAY: $143.82 cardinal (9.57% of AUM)
- NASDAQ:ALKS: $99.33 cardinal (6.61% of AUM)
- NASDAQ:TYRA: $88.73 cardinal (5.91% of AUM)
- NASDAQ:XENE: $80.68 cardinal (5.37% of AUM)
- NASDAQ:SYRE: $78.24 cardinal (5.21% of AUM)
As of February 17, 2026, Nuvalent shares were priced astatine $102.24, up 29% implicit the erstwhile twelvemonth and good outperforming the S&P 500’s astir 13% summation successful the aforesaid period.

Metric

Value

Price (as of marketplace adjacent 2026-02-17)	$102.24
Market capitalization	$7.43 billion
Net income (TTM)	($381.44 million)
One-year terms change	29.11%

Nuvalent develops targeted therapies for cancer, with pb merchandise candidates NVL-520 (a ROS1-selective inhibitor) and NVL-655 (an ALK-selective inhibitor) presently successful early-stage objective trials.
The institution operates a clinical-stage biopharmaceutical model, investing successful probe and improvement to beforehand caller oncology treatments, with aboriginal gross imaginable babelike connected palmy regulatory support and commercialization.
Nuvalent targets oncologists and healthcare providers treating patients with cancers driven by circumstantial familial mutations, focusing connected unmet needs successful the oncology market.

Nuvalent, Inc. is simply a Cambridge-based biotechnology institution specializing successful the find and improvement of precision therapies for cancer. The institution leverages its expertise successful kinase inhibitor plan to code absorption and cardinal tense strategy challenges successful targeted oncology. With a pipeline of differentiated objective candidates, Nuvalent aims to present transformative therapies for patients with constricted attraction options.

Cutting Nuvalent from 9% of assets to 4% successful a azygous 4th looks similar a connection astir hazard tolerance aft a run.

To beryllium clear, however, Nuvalent is not a breached story. The institution ended 2025 with astir $1.4 cardinal successful currency and expects runway into 2029. The FDA has accepted its NDA for zidesamtinib successful ROS1 affirmative non tiny compartment lung cancer, with a PDUFA day acceptable for September 18, and an ALK programme filing planned successful the archetypal fractional of this year. Those are tangible catalysts.

Shares beryllium supra $100 aft a 29% 1 twelvemonth gain. And for a money that concentrates successful aboriginal signifier names similar Relay, Tyra and Xene, trimming into spot tin beryllium astir superior recycling, not mislaid faith.

Ultimately, semipermanent investors should absorption connected 2 questions. Does Nuvalent person regulatory momentum into commercialized execution successful 2026. And tin its pipeline prolong maturation beyond the archetypal launch. If the reply is yes, volatility astir ownership changes whitethorn extremity up looking similar noise, not signal.

Read Entire Article